Ashwani Verma

Chris Schott

David Amsellem

Jason Gerberry

Keonhee Kim

Les Sulewski

Matthew Dellatorre

Umer Raffat

Umer Rappat

- Teva Pharmaceutical Industries (Immunering) announced extraordinary nine-month overall survival data from its phase IIa trial of atabinib in first-line pancreatic cancer patients, showing **94% overall survival at six months** and **86% at nine months**.  **[818686_2160731_2]** **[818686_2160731_7]** 
- The company secured **$175 million** through an underwritten offering and a **$25 million** private placement, which included a strategic investment from **Sanofi**.  **[818686_2160731_1]** 
- This financing, combined with current cash, is expected to fund the company into **2029**, covering the planned phase III study for atabinib in first-line pancreatic cancer, new phase II studies in lung cancer, and the preclinical pipeline.  **[818686_2160731_1]** **[818686_2160731_6]** **[818686_2160731_7]** 
- Teva plans to initiate a pivotal phase III study for atabinib in first-line pancreatic cancer by the end of 2025, with the first patient dosed by mid-2026 and a top-line readout expected approximately two years later.  **[818686_2160731_6]**

Teva Pharmaceutical Industries Reports Positive Atabinib Phase IIa Results and Secures Funding

- Teva's innovative business grew **27%** in Q2, contributing to increased gross margin, EBITDA, and EPS, as the company transitions towards a biopharma focus.  **[818686_2155142_1]** 
- Key product projections include Austedo reaching **$3 billion** in peak sales, the Ajovy franchise **$1.5 to $2 billion**, and the upcoming olanzapine LAI **$1.5 billion to $2 billion**.  **[818686_2155142_1]** **[818686_2155142_9]** 
- The company is committed to paying down debt, aiming for investment-grade status by the **second half of next year**, which is expected to free up **$400 million** in cash by 2027.  **[818686_2155142_2]** 
- An operational efficiency program is underway to save **$700 million by 2027**, with two-thirds of savings expected by the end of 2026, primarily through COGS improvements, to offset the loss of Revlimid.  **[818686_2155142_1]** **[818686_2155142_3]** **[818686_2155142_4]** 
- The launch of olanzapine LAI next year is anticipated to be excellent, with Teva planning to maintain its value proposition rather than offering discounts for rapid market access.  **[818686_2155142_4]** **[818686_2155142_8]**

Teva Pharmaceutical Industries Highlights Innovative Business Growth and Strategic Financial Goals

- Teva announced positive Phase 3 Solaris data for its Elanzapin LAI (long-acting injectable) formulation for schizophrenia.  **[818686_2152752_1]** 
- The subcutaneous formulation demonstrated **no Post-Injection Delirium and Sedation Syndrome (PDSS)** across approximately **4,000 injections** in the development program, addressing a key safety concern with current Elanzapin injections.  **[818686_2152752_2]** **[818686_2152752_6]** 
- The study showed statistically and clinically meaningful efficacy, with good long-term tolerability over **48 weeks**, and low discontinuation rates due to side effects.  **[818686_2152752_2]** **[818686_2152752_5]** 
- Teva is confident in the data for regulatory submission, having engaged with the FDA since 2016 and implemented robust monitoring to ensure a "picture-perfect submission".  **[818686_2152752_6]** **[818686_2152752_12]** 
- This new formulation is expected to fill a significant treatment gap in schizophrenia, offering an easy-to-use option without the need for dual injection, oral co-treatment, or loading doses.  **[818686_2152752_7]**

Teva Presents Positive Phase 3 Data for Elanzapin LAI in Schizophrenia

TEVA PHARMACEUTICAL INDUSTRIES (TEVA)